AU2021344091A1 - Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor - Google Patents
Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor Download PDFInfo
- Publication number
- AU2021344091A1 AU2021344091A1 AU2021344091A AU2021344091A AU2021344091A1 AU 2021344091 A1 AU2021344091 A1 AU 2021344091A1 AU 2021344091 A AU2021344091 A AU 2021344091A AU 2021344091 A AU2021344091 A AU 2021344091A AU 2021344091 A1 AU2021344091 A1 AU 2021344091A1
- Authority
- AU
- Australia
- Prior art keywords
- week
- salt
- oxo
- dimetylphenyl
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078833P | 2020-09-15 | 2020-09-15 | |
| US63/078,833 | 2020-09-15 | ||
| PCT/JP2021/033854 WO2022059691A1 (en) | 2020-09-15 | 2021-09-15 | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021344091A1 true AU2021344091A1 (en) | 2023-05-25 |
| AU2021344091A9 AU2021344091A9 (en) | 2024-08-08 |
Family
ID=80776688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021344091A Pending AU2021344091A1 (en) | 2020-09-15 | 2021-09-15 | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230338342A1 (https=) |
| EP (1) | EP4213841A4 (https=) |
| JP (1) | JP2023541430A (https=) |
| KR (1) | KR20230067646A (https=) |
| AU (1) | AU2021344091A1 (https=) |
| WO (1) | WO2022059691A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130005678A1 (en) * | 2010-03-30 | 2013-01-03 | Clavis Pharma Asa | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate |
| US10889555B2 (en) * | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
| US20200405697A1 (en) * | 2017-11-29 | 2020-12-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor Agent |
-
2021
- 2021-09-15 US US18/044,978 patent/US20230338342A1/en active Pending
- 2021-09-15 WO PCT/JP2021/033854 patent/WO2022059691A1/en not_active Ceased
- 2021-09-15 JP JP2023516473A patent/JP2023541430A/ja active Pending
- 2021-09-15 EP EP21869377.8A patent/EP4213841A4/en active Pending
- 2021-09-15 KR KR1020237012412A patent/KR20230067646A/ko active Pending
- 2021-09-15 AU AU2021344091A patent/AU2021344091A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4213841A1 (en) | 2023-07-26 |
| WO2022059691A1 (en) | 2022-03-24 |
| JP2023541430A (ja) | 2023-10-02 |
| US20230338342A1 (en) | 2023-10-26 |
| AU2021344091A9 (en) | 2024-08-08 |
| TW202227059A (zh) | 2022-07-16 |
| KR20230067646A (ko) | 2023-05-16 |
| EP4213841A4 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4213842B1 (en) | Ribonucleotide reductase inhibitor for use in a method of treating tumors | |
| WO2022059691A1 (en) | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor | |
| CN113038953B (zh) | 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法 | |
| WO2025034702A1 (en) | Rmc-6291 for use in the treatment of ras protein-related disease or disorder | |
| WO2025019318A2 (en) | Methods of treating a ras related disease or disorder | |
| US20240238300A1 (en) | Treatment methods for subjects with cancer having an aberration in egfr and/or her2 | |
| AU2024307787A1 (en) | Treatment methods for subjects with non-small cell lung cancer having an aberration in egfr | |
| AU2022355189B2 (en) | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator | |
| RU2848459C1 (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| RU2859365C2 (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| TWI914404B (zh) | 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 | |
| US20240408100A1 (en) | Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway | |
| WO2026015825A1 (en) | Use of ras inhibitor for treating pancreatic cancer | |
| HK40129790A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| WO2025255438A1 (en) | Methods of treating a ras protein-related disease or disorder | |
| HK40055650A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| HK40051935A (en) | Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |